Loading the session
Loading the session
Loading instrument
$108.99
+4.36%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +4.5% (SPY −1.6%, XLV +13.5%). 3 months: +11.1% (SPY −0.4%, XLV +15.5%). 1 year: −39.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: INSM, SPY and XLV · as of 4 Nov 2026
29 Oct 2026 volume of 11.2M shares was 3.8× the average of the 30 sessions before it (2.9M), as the price rose 15.1%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
The 4 Nov 2026 close of $110.00 was 1.5% below its 50-day average ($111.66) and 11.7% below its 200-day average ($124.61). It has closed below the 200-day for 142 sessions, since 15 Apr 2026. The 50-day average crossed below the 200-day on 1 Apr 2026, 150 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $110.00 on 4 Nov 2026: 48.3% below the 52-week high of $212.75 (2 Dec 2025) and 21.7% above the low of $90.39 (10 Jun 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
13.5M shares were sold short at the 15 Oct 2026 settlement, 6.1% of the 219.4M shares outstanding; covering them would take 4.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
August 6, 2026
+33.86%June 10, 2025
+28.65%May 28, 2024
+118.45%